In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.
During the 2020 American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will take part in a debate about whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready for "prime time" in cardiovascular primary prevention.
Transcript
At ADA, you will take part in a debate about SGLT2 inhibitors and GLP-1 receptor agonists and whether or not they're ready for prime time in cardiovascular prevention. What will that discussion look like?
So, the upcoming ADA, I'll be debating Mikhail Kosiborod [MD] about whether the SGLT2 inhibitors and/or the GLP-1 receptor agonists are ready for prime time for primary prevention of adverse chronic cardiovascular disease. I've worked very closely with Mikhail for over 20 years, we're very close friends, and I look forward to humiliating him on the international stage.
So, I've assigned [to take the position] that they're not ready for prime time. In most of my answer, I think that SGLT2 inhibitors from the DECLARE in the CANVAS trials data pretty clearly don't affect atherosclerotic cardiovascular disease risk in the primary prevention population. So, I think that's a reasonably easy answer if we're talking about 3-point MACE [major adverse cardiac event] cardiovascular death, MI [myocardial infarction, and stroke.
The counter to that is in the GLP-1receptor agonist, in general, and the meta-analysis and specifically with dulaglutide and the REWIND trial, the efficacy for cardiovascular atherosclerotic cardiovascular disease outcomes looks to be independent of prevalent atherosclerotic cardiovascular disease (ASCVD). But importantly in REWIND, if you look into the details of the data, the absolute risk reduction in the primary prevention cohort was 0.5%. So, that means you have to treat 200 patients for 3 years to derive that single clinical event reduced, for a drug that's priced often at $300 or $400 a month. It becomes cost prohibitive. So, I'm going to use an economics argument for the GLP-1 receptor agonist.
Now, flipping back to the SGLT2 inhibitors. If we're talking about primary prevention of cardiovascular death, MI, and stroke, it's a reasonably easy answer. It's a very different answer, if you look at heart failure. So, I think that the SGLT inhibitors are, in fact, ready for prime time for heart failure risk reduction independent of prevalent ASCVD. I think probably will need to have multiple risk factors just to get to a level of absolute risk that will justify the absolute risk reduction and the cost efficiency. So, I don't think every single patient with type 2 diabetes should be started on an SGLT2 inhibitor to prevent heart failure, but I think we should have a very low bar and not require clinically manifest cardiovascular disease to trigger that decision.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More